Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tissue Regenix ( (GB:TRX) ) has provided an update.
Tissue Regenix has been granted a European patent for its innovative decellularisation technology, dCELL®, by the European Patent Office. This patent strengthens the company’s intellectual property portfolio and supports its expansion in the global regenerative medicine and implantable device markets. The dCELL technology is crucial for Tissue Regenix’s product development, as it provides a tissue scaffold that supports growth and remodeling without rejection by the patient’s body. The patent adds to existing protections in the U.S. and U.K., reinforcing the company’s industry leadership and commitment to innovation.
More about Tissue Regenix
Tissue Regenix is a leading medical device company in regenerative medicine, specializing in decellularisation technology (dCELL®) that removes DNA and cellular material from animal and human soft tissue. This technology creates an acellular tissue scaffold that is not rejected by the patient’s body, facilitating the repair of diseased or damaged body structures. The company’s applications address clinical needs in sports medicine, foot and ankle injuries, and wound care. In 2017, Tissue Regenix acquired CellRight Technologies, a biotech company focused on regenerative medicine and innovative tissue scaffolds for various surgical procedures.
YTD Price Performance: -40.0%
Average Trading Volume: 41,414
Technical Sentiment Signal: Buy
Current Market Cap: £25.64M
Learn more about TRX stock on TipRanks’ Stock Analysis page.